For patients with severe asthma in the United Kingdom, the path to biologic therapy is often drawn out. While biologic injections such as omalizumab and mepolizumab can dramatically reduce exacerbations, many patients face months of prior authorization delays. In the interim, they frequently rely on rescue inhalers—short-acting beta-agonists like salbutamol—to manage symptoms. This workaround masks underlying disease progression and increases the risk of severe attacks and emergency hospital visits. The situation reveals a systemic failure in which administrative hurdles inadvertently shift costs and clinical risks onto patients.

Severe asthma affects roughly 200,000 people in the UK, according to Asthma+Lung UK. For these individuals, standard inhaler therapy is often insufficient, and biologics can be transformative. Yet the journey to receive these drugs is riddled with delays. Prior authorization—a process in which NHS trusts review and approve expensive treatments—can take 6 to 12 months from specialist referral to first injection. During this time, patients often increase their use of rescue inhalers, sometimes puffing 4 to 6 times daily just to get by.

This reliance on short-acting beta-agonists is concerning. International guidelines, including those from the Global Initiative for Asthma, recommend against frequent use of rescue inhalers alone, as it is linked to a higher risk of exacerbations and even death. A 2023 audit by the Royal College of Physicians found that overuse of salbutamol was associated with a 40% increase in emergency department visits among severe asthma patients. Yet without timely access to biologics, many patients have no alternative.

Patient surveys paint a picture of frustration. In a 2024 survey by Asthma+Lung UK, 68% of respondents awaiting biologic therapy reported that their quality of life had worsened during the waiting period. They described missed work, disrupted sleep, and anxiety about sudden attacks. The inhaler treadmill—using rescue puffs as a stopgap—becomes a coping mechanism, but one that carries its own risks. As one patient noted, "I felt like I was just managing the symptoms, not treating the disease."

NICE has approved several biologics for severe asthma, including omalizumab (Xolair), mepolizumab (Nucala), and benralizumab (Fasenra). These drugs can reduce exacerbations by 50 to 70% and improve lung function. But the approval process requires patients to first demonstrate failure of three prior step-therapies, including high-dose inhaled corticosteroids and long-acting beta-agonists. Then, local formularies—managed by Integrated Care Boards (ICBs)—must sign off, often with additional documentation demands.

How Prior Authorization Stalls Biologic Start in Practice

The prior authorization process for biologics in the UK involves multiple steps. A specialist at a hospital clinic must submit a detailed application to the local ICB, including evidence of prior treatment failures, spirometry results, and symptom scores. The ICB then reviews the request, sometimes requesting further information or a second opinion. According to a 2024 analysis by the British Thoracic Society, the average approval time across England is 8 to 14 weeks, but this varies widely by region.

Some patients face even longer waits. A study at a London teaching hospital found that 30% of patients referred for biologic therapy abandoned the process during the wait—either because their condition worsened, they moved, or they simply gave up. Those who persist often experience multiple exacerbations while waiting. Each severe attack costs the NHS an estimated £1,500 to £3,000 in emergency care, not to mention the personal toll on patients.

The administrative burden is not trivial. Prior authorization requires staff time from both the hospital and the ICB, including nurses, pharmacists, and administrators who could otherwise focus on direct patient care. A 2023 report from the Health Foundation estimated that the administrative cost of prior authorization for biologics alone amounts to roughly £12 million annually across the NHS. This is money that could be redirected to patient services.

Critics argue that the system is overly cautious. "The stepwise approach was designed to ensure cost-effectiveness, but it often delays care for those who need it most," says Dr. Sarah Jenkins, a respiratory consultant in Manchester. "We know the biologics work, but the hoops we have to jump through are exhausting." Some specialists have called for a fast-track approval for patients with two or more exacerbations per year, a criterion already used in some other countries.

Rescue Inhalers as De Facto Maintenance: A Costly Workaround

While awaiting biologics, many patients turn to rescue inhalers as their primary therapy. Salbutamol inhalers are cheap—costing the NHS about £1.50 per unit—but their widespread use as a maintenance substitute adds up. NHS prescribing data show that roughly 25% of severe asthma patients rely solely on short-acting beta-agonists, without regular inhaled corticosteroids. This pattern is directly counter to guidelines and is associated with poor outcomes.

The financial cost is substantial. The NHS spends around £100 million annually on salbutamol inhalers, much of it for patients who would be better served by biologics or combination inhalers. Meanwhile, the cost of treating exacerbations triggered by uncontrolled asthma adds hundreds of millions more. A 2022 modeling study from the University of Oxford estimated that each month of delay in starting biologic therapy adds roughly £800 in avoidable healthcare costs per patient, including emergency visits and hospitalizations.

Patients themselves bear the burden. Frequent inhaler use can lead to tachyphylaxis—a reduced response over time—and side effects like tremor and tachycardia. More importantly, it does not address the underlying inflammation. "Using salbutamol four times a day is like putting a band-aid on a deep wound," says Dr. Jenkins. "The inflammation continues to damage the airways, leading to irreversible lung function decline."

Some international guidelines now recommend as-needed combination inhalers containing both a corticosteroid and a fast-acting bronchodilator (such as ICS-formoterol) instead of plain salbutamol. But adoption in the UK has been slow, particularly in primary care. The result is that many patients remain on outdated regimens while they wait for biologics, perpetuating a cycle of poor control and high healthcare utilization.

The Equity Gap: Postcode Lotteries in Biologic Access

Access to biologic therapy in the UK is not uniform. Approval rates vary significantly by region, creating what patient groups call a "postcode lottery." According to data from Asthma+Lung UK, some ICBs approve biologics for 80% of eligible patients, while others approve only 40%. The reasons include differences in local formularies, budget constraints, and variations in specialist expertise.

Deprived areas often fare worse. A 2024 analysis by the Northern Health Science Alliance found that patients in the North West of England faced waits that were 50% longer than those in the South East, even after adjusting for disease severity. This disparity mirrors broader health inequalities in the UK, where poverty is linked to worse asthma outcomes. Black and South Asian patients, who already have higher rates of severe asthma, are also less likely to receive biologics compared to white patients, according to a 2023 study in Thorax.

Rural patients face additional barriers. Many specialist centers for biologic administration are located in major cities, requiring patients in remote areas to travel 2 hours or more for monthly injections. Some ICBs offer home care services, but availability is inconsistent. A 2022 report from the National Asthma and COPD Audit Programme noted that patients in rural Scotland had a 30% lower likelihood of starting biologics within 6 months of referral compared to urban counterparts.

These inequities are not inevitable. NICE guidance recommends biologics for patients with severe asthma who meet specific criteria, but local implementation is left to ICBs. "The guidance is clear, but the funding and infrastructure are not," says Dr. James Carter, a health policy researcher at the London School of Hygiene and Tropical Medicine. "Some ICBs have made it a priority; others have not. The result is a system where your postcode determines your treatment."

Health System Costs of Delayed Biologic Therapy

The financial impact of delayed biologic therapy extends beyond the cost of rescue inhalers. Each severe asthma exacerbation that leads to an emergency department visit or hospitalization costs the NHS between £1,500 and £3,000. With an estimated 60,000 emergency admissions for asthma annually in the UK, a significant proportion could be prevented with timely biologic use. Clinical trials show that biologics reduce exacerbations by 50 to 70%, meaning that every month of delay across the patient population translates into thousands of avoidable events.

Productivity losses add to the economic burden. Uncontrolled asthma results in missed work and school days, with the UK economy losing an estimated £1.2 billion annually due to asthma-related absenteeism, according to a 2023 report from the Centre for Economics and Business Research. For patients awaiting biologics, the inability to work or perform daily activities compounds the personal cost. Many report feeling "trapped" by their condition, unable to plan for the future.

The administrative machinery of prior authorization itself consumes resources. Each application requires time from specialists, pharmacists, and administrators. A 2024 time-motion study at a large NHS trust found that processing a single biologic prior authorization took an average of 3.5 hours of staff time across multiple departments. With thousands of applications per year, the cumulative cost is substantial. Some of that time could be redirected to patient education or monitoring.

There is also an opportunity cost. Money spent on managing the consequences of delayed therapy—emergency visits, hospitalizations, and rescue inhalers—could be used to expand biologic access. A 2025 analysis by the King's Fund suggested that investing in faster biologic approvals could save the NHS £50 million annually within 3 years, primarily through reduced exacerbations. Yet the upfront cost of biologics, which can exceed £10,000 per patient per year, makes ICBs hesitant to approve them quickly.

What Other High-Income Systems Do Differently

Prior authorization challenges are not unique to the UK, but some high-income countries have found ways to streamline access. In Australia, the Pharmaceutical Benefits Scheme (PBS) allows biologic prescribing after two step-therapy failures, rather than three, and approvals are typically processed within 2 weeks. The system uses a centralized electronic portal that reduces paperwork and standardizes criteria. As a result, Australian patients start biologics roughly 4 months sooner than UK counterparts, according to a 2023 comparative study.

Germany's sickness funds—the statutory health insurers—approve biologics within an average of 2 weeks, thanks to a digital prior authorization system that integrates with electronic health records. Physicians submit requests online, and decisions are automated for patients meeting clear criteria. If a request is denied, the insurer must provide a detailed rationale within 48 hours, and appeals are fast-tracked. This transparency reduces delays and frustration.

Canada has adopted a different model: specialized severe asthma clinics that co-locate prescribing and injection services in a single visit. Patients are assessed by a multidisciplinary team—respiratory specialist, nurse, pharmacist—and can receive their first biologic dose on the same day if eligible. This eliminates the back-and-forth between primary care, specialist, and insurer. A 2022 study from Ontario found that this model reduced time to treatment by 60% compared to traditional referral pathways.

Japan's national protocol uses a step-up approach that includes inhaled corticosteroid/long-acting beta-agonist combinations before biologics, but the approval process is straightforward. The national health insurance system sets explicit criteria, and once a specialist confirms a patient meets them, approval is automatic. There is no local formulary variation, ensuring equity across regions. The UK could learn from these examples by adopting standardized digital submission, reducing the number of required step failures, and mandating maximum turnaround times.

Reforming the Pathway: From Prior Authorization to Prior Harm

There is growing consensus that the current system needs reform. The Royal College of Physicians has called for a "fast-track" biologic pathway for patients with two or more exacerbations per year, regardless of prior step-therapy failures. Asthma+Lung UK has proposed automatic approval for patients who meet NICE criteria, with prior authorization reserved for exceptions. Some ICBs are piloting nurse-led prescribing, where respiratory nurses initiate biologics without requiring a separate specialist review, cutting weeks off the process.

Digital prior authorization platforms are also showing promise. A pilot in the South West of England reduced processing time by 60% by allowing electronic submission and automated checks against patient records. The platform flags incomplete applications immediately, reducing back-and-forth. Early results suggest that such systems could be scaled nationally, though they require investment in IT infrastructure and training.

Patient advocacy groups are pushing for greater transparency. Currently, when a prior authorization is denied, patients and specialists often receive a vague explanation—"does not meet local criteria"—without specifics. Groups like the Severe Asthma Patient Network are demanding that ICBs publish their denial rates and rationales, so that patients can understand their options and appeal if needed. Some have also called for an independent review board to adjudicate disputes.

Streamlining approvals could increase biologic prescribing, raising short-term drug costs for ICBs. However, modeling suggests that the savings from reduced exacerbations and hospitalizations would offset much of the expense within 2 years. The challenge is that ICBs face annual budget constraints, making it difficult to invest upfront. A national ring-fenced fund for biologics, similar to that used for hepatitis C treatments in the mid-2010s, could help bridge this gap.

The path forward requires a shift in mindset—from viewing prior authorization as a cost-control tool to recognizing it as a clinical decision that can cause harm when delayed. As Dr. Jenkins puts it: "Every week a patient waits for a biologic is a week they are at risk of a life-threatening attack. We need to ask ourselves: is the administrative burden worth the risk?" The answer, for many, is no.

For related reading, see how prior authorization affects other conditions: Medicare Part D Prior Authorization and German Maternity Hospitals. Also, the challenge of antibiotic resistance in the UK is explored in this piece on gonorrhea.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for guidance on asthma management and treatment options.